July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
First real world analysis of safety in 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant treated eyes receiving supplemental ocular steroid injection for diabetic macular edema (DME)
Author Affiliations & Notes
  • Victor H Gonzalez
    Valley Retina Institute PA, Edinburg, Texas, United States
  • Footnotes
    Commercial Relationships   Victor Gonzalez, Abbvie (F), Alcon/Novartis (C), Alimera (C), Allegro Ophthalmics (F), Allergan (C), Astellas Institute for Regenerative Medicine (F), Bausch and Lomb (C), Bayer (C), Beaver-Visitec International, Inc (C), Boehringer Ingelheim (F), Clearside Biomedical (F), DRCR Net (F), Eyegate Pharma (F), Genentech (C), Graybug Vision, Inc (F), Iconic Therapeutics (F), Insite Vision INC (F), Mallinckrodt ARD Inc. (F), Opternative (F), Panoptica (C), Regeneron (C), Santen (C), Thrombogenics, Inc (C), Topcon (C), Valeant (C)
  • Footnotes
    Support  Statistical support
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2636. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Victor H Gonzalez; First real world analysis of safety in 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant treated eyes receiving supplemental ocular steroid injection for diabetic macular edema (DME). Invest. Ophthalmol. Vis. Sci. 2019;60(9):2636.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : It has been shown that the IOP signal after the prior steroid is highly predictive of the intraocular pressure (IOP) response post FAc. However, studies have not generally provided detail on the relationship of IOP response to steroids administered following with 0.2 ug/day FAc. The current analysis looks at the IOP response in eyes that have received at least one supplemental ocular steroid injection after FAc.

Methods : Retrospective chart review of 0.19 mg FAc-treated eyes that had supplemental ocular steroid injections after FAc to treat their DME. IOP was collected prior to the steroid challenge (as indicated by treating physician), and at various timepoints through the follow up period.

Results : There were 65 eyes collected from chart reviews totaling 337 eyes (12 sites) that had at least one supplemental ocular steroid injection after FAc. 151 total supplemental steroid injections (79% dexamethasone, 13% triamcinolone acetonide, 8% FAc) were given (range 1-10). Mean follow up was 671 days (range 162-1265 days). Mean time to first supplemental steroid was 273 days post FAc implant. All eyes were treated per US label and had received a steroid challenge before FAc. Very few eyes had an IOP >25 mmHg post FAc despite the supplemental steroid injections further supporting the predictability of IOP response. Two patients had an IOP >30 mmHg after supplemental steroid and one required incisional surgery. Overall, the mean IOP change was < 3 mmHg over the follow-up period with up to 3 or more additional steroids. Of the 45 eyes that received one supplemental steroid post FAc, the mean IOP increase was 2 mmHg. Of the eyes that received two supplemental steroids, the mean IOP increase was 2mmHg. Of the eyes that received three supplemental steroids, the mean IOP increase was 2.5mmHg.

Conclusions : The steroid challenge is predictive of the IOP response post FAc even in the limited set of eyes that required supplemental intraocular steroid.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Absolute IOP in mmHg over time

Absolute IOP in mmHg over time

 

Mean, Max, and Last IOP of additional steroid

Mean, Max, and Last IOP of additional steroid

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×